{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["DepoCyt", "cancer therapy", "chemotherapy", "liposomal ara-C", "liposomal cytarabine", "liposomal cytosine arabinoside"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31771220", "DateCompleted": {"Year": "2020", "Month": "08", "Day": "28"}, "DateRevised": {"Year": "2020", "Month": "08", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "11", "Day": "23"}], "Language": ["eng"], "ELocationID": ["773", "10.3390/biom9120773"], "Journal": {"ISSN": "2218-273X", "JournalIssue": {"Volume": "9", "Issue": "12", "PubDate": {"Year": "2019", "Month": "Nov", "Day": "23"}}, "Title": "Biomolecules", "ISOAbbreviation": "Biomolecules"}, "ArticleTitle": "Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine.", "Abstract": {"AbstractText": ["Cancer is the second leading cause of death worldwide. The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer patients. In the last decades, chemotherapy has been well developed. Nonetheless, administration of the drug is not always successful, as limited drug dosage can reach the tumor cells.. In this context, the possibility to use an encapsulated anti-cancer drug may potentially solve the problem. Liposomal cytarabine is a formulation with pronounced effectiveness in lymphomatous meningitis and reduced cardiotoxicity if compared to liposomal anthracyclines. Thus, the future liposomal cytarabine use could be extended to other diseases given its reduction in cytotoxic side effects compared to the free formulation. This review summarizes the chemistry and biology of liposomal cytarabine, with exploration of its clinical implications."]}, "AuthorList": [{"Identifier": ["0000-0002-6900-9797"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Student Research Committee, School of Medicine, Bam University of Medical Sciences, Bam 44340847, Iran."}], "LastName": "Salehi", "ForeName": "Bahare", "Initials": "B"}, {"Identifier": ["0000-0001-9056-6435"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Biology, Faculty of Medicine, Nigde \u00d6mer Halisdemir University, Campus, 51240 Nigde, Turkey."}], "LastName": "Selamoglu", "ForeName": "Zeliha", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Morphology and Systematic of Plants, Institute of Botany and Botanical Garden \"Jevremovac,\" Faculty of Biology, University of Belgrade, Belgrade 11000, Serbia."}], "LastName": "S Mileski", "ForeName": "Ksenija", "Initials": "K"}, {"Identifier": ["0000-0003-3156-2500"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "O.U. Endocrinology, Department of Medicine (DIMED), University of Padova, via Ospedale 105, 35128 Padova, Italy."}, {"Identifier": [], "Affiliation": "AIROB, Associazione Italiana per la Ricerca Oncologica di Base, 35128 Padova, Italy."}], "LastName": "Pezzani", "ForeName": "Raffaele", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "AIROB, Associazione Italiana per la Ricerca Oncologica di Base, 35128 Padova, Italy."}, {"Identifier": [], "Affiliation": "Venetian Institute for Molecular Science and Experimental Technologies, VIMSET. Pz Milani, 4 30010 Liettoli di Campolongo Maggiore, VE, Italy."}], "LastName": "Redaelli", "ForeName": "Marco", "Initials": "M"}, {"Identifier": ["0000-0003-4174-4586"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China."}], "LastName": "Cho", "ForeName": "William C", "Initials": "WC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran 1991953381, Iran."}, {"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran 11369, Iran."}], "LastName": "Kobarfard", "ForeName": "Farzad", "Initials": "F"}, {"Identifier": ["0000-0003-0177-7922"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 23871, Iran."}], "LastName": "Rajabi", "ForeName": "Sadegh", "Initials": "S"}, {"Identifier": ["0000-0003-3183-7623"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Nutrition and Dietetics, Faculty of Pharmacy, University of Concepcion, Concepcion 4070386, Chile."}, {"Identifier": [], "Affiliation": "Universidad de Concepci\u00f3n, Unidad de Desarrollo Tecnol\u00f3gico, UDT, Concepcion 4070386, Chile."}], "LastName": "Martorell", "ForeName": "Miquel", "Initials": "M"}, {"Identifier": ["0000-0002-0892-5425"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Forestry, North Eastern Regional Institute of Science and Technology, (Deemed To Be University-MHRD), Nirjuli (Itanagar) 791109, India."}], "LastName": "Kumar", "ForeName": "Pradeep", "Initials": "P"}, {"Identifier": ["0000-0002-5934-5201"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal."}, {"Identifier": [], "Affiliation": "Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal."}], "LastName": "Martins", "ForeName": "Nat\u00e1lia", "Initials": "N"}, {"Identifier": ["0000-0002-9403-2155"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Engineering Design, Indian Institute of Technology Madras, Chennai 600036, India."}], "LastName": "Subhra Santra", "ForeName": "Tuhin", "Initials": "T"}, {"Identifier": ["0000-0002-7301-8151"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zabol Medicinal Plants Research Center, Zabol University of Medical Sciences, Zabol 61615-585, Iran."}], "LastName": "Sharifi-Rad", "ForeName": "Javad", "Initials": "J"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Biomolecules", "NlmUniqueID": "101596414", "ISSNLinking": "2218-273X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Liposomes"}, {"RegistryNumber": "04079A1RDZ", "NameOfSubstance": "Cytarabine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["administration & dosage", "chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["administration & dosage", "chemistry"], "DescriptorName": "Cytarabine"}, {"QualifierName": [], "DescriptorName": "Drug Compounding"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Liposomes"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Neoplasms"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA. 2018;68:7\u201330. doi: 10.3322/caac.21442.", "ArticleIdList": ["10.3322/caac.21442", "29313949"]}, {"Citation": "Salehi B., Zucca P., Sharifi-Rad M., Pezzani R., Rajabi S., Setzer W.N., Varoni E.M., Iriti M., Kobarfard F., Sharifi-Rad J. Phytotherapeutics in cancer invasion and metastasis. Phytother. Res. 2018 doi: 10.1002/ptr.6087.", "ArticleIdList": ["10.1002/ptr.6087", "29672977"]}, {"Citation": "Barabadi H., Alizadeh A., Ovais M., Ahmadi A., Shinwari Z., Muthupandian S. The efficacy of green nanoparticles against cancerous and normal cell lines: A systematic review and meta-analysis. IET Nanobiotechnol. 2017;12:377\u2013391. doi: 10.1049/iet-nbt.2017.0120.", "ArticleIdList": ["10.1049/iet-nbt.2017.0120", "29768219"]}, {"Citation": "Barabadi H., Ovais M., Shinwari Z.K., Saravanan M. Anti-cancer green bionanomaterials: Present status and future prospects. Green Chem. Lett. Rev. 2017;10:285\u2013314. doi: 10.1080/17518253.2017.1385856.", "ArticleIdList": ["10.1080/17518253.2017.1385856"]}, {"Citation": "Mishra A.P., Salehi B., Sharifi-Rad M., Pezzani R., Kobarfard F., Sharifi-Rad J., Nigam M. Programmed Cell Death, from a Cancer Perspective: An Overview. Mol. Diagn. Ther. 2018;22:281\u2013295. doi: 10.1007/s40291-018-0329-9.", "ArticleIdList": ["10.1007/s40291-018-0329-9", "29560608"]}, {"Citation": "Yang J., Su H., Sun W., Cai J., Liu S., Chai Y., Zhang C. Dual Chemodrug-Loaded Single-Walled Carbon Nanohorns for Multimodal Imaging-Guided Chemo-Photothermal Therapy of Tumors and Lung Metastases. Theranostics. 2018;8:1966. doi: 10.7150/thno.23848.", "ArticleIdList": ["10.7150/thno.23848", "PMC5858512", "29556368"]}, {"Citation": "Leriche G., Cifelli J.L., Sibucao K.C., Patterson J.P., Koyanagi T., Gianneschi N.C., Yang J. Characterization of drug encapsulation and retention in archaea-inspired tetraether liposomes. Organ. Biomol. Chem. 2017;15:2157\u20132162. doi: 10.1039/C6OB02832B.", "ArticleIdList": ["10.1039/C6OB02832B", "28221378"]}, {"Citation": "Siontorou C.G., Nikoleli G.P., Nikolelis D.P., Karapetis S.K. Artificial Lipid Membranes: Past, Present, and Future. Membranes. 2017;7:38. doi: 10.3390/membranes7030038.", "ArticleIdList": ["10.3390/membranes7030038", "PMC5618123", "28933723"]}, {"Citation": "Weissig V. Liposomes Came First: The Early History of Liposomology. Methods Mol. Biol. 2017;1522:1\u201315.", "ArticleIdList": ["27837526"]}, {"Citation": "Riaz M.K., Riaz M.A., Zhang X., Lin C., Wong K.H., Chen X., Zhang G., Lu A., Yang Z. Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review. Int. J. Mol. Sci. 2018;19:195. doi: 10.3390/ijms19010195.", "ArticleIdList": ["10.3390/ijms19010195", "PMC5796144", "29315231"]}, {"Citation": "Bally M.B., Mayer L.D., Loughrey H., Redelmeier T., Madden T.D., Wong K., Harrigan P.R., Hope M.J., Cullis P.R. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem. Phys. Lipids. 1988;47:97\u2013107. doi: 10.1016/0009-3084(88)90078-3.", "ArticleIdList": ["10.1016/0009-3084(88)90078-3", "2457454"]}, {"Citation": "Fatima M.T., Islam Z., Ahmad E., Barreto G.E., Md Ashraf G. Ionic gradient liposomes: Recent advances in the stable entrapment and prolonged released of local anesthetics and anticancer drugs. Biomed. Pharmacother. 2018;107:34\u201343. doi: 10.1016/j.biopha.2018.07.138.", "ArticleIdList": ["10.1016/j.biopha.2018.07.138", "30077836"]}, {"Citation": "Ma P., Dong X., Swadley C.L., Gupte A., Leggas M., Ledebur H.C., Mumper R.J. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J. Biomed. Nanotechnol. 2009;5:151\u2013161. doi: 10.1166/jbn.2009.1021.", "ArticleIdList": ["10.1166/jbn.2009.1021", "PMC2805476", "20055093"]}, {"Citation": "Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin. Drug Deliv. 2011;8:565\u2013580. doi: 10.1517/17425247.2011.566552.", "ArticleIdList": ["10.1517/17425247.2011.566552", "21492058"]}, {"Citation": "Abraham S.A., McKenzie C., Masin D., Ng R., Harasym T.O., Mayer L.D., Bally M.B. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin. Cancer Res. 2004;10:728\u2013738. doi: 10.1158/1078-0432.CCR-1131-03.", "ArticleIdList": ["10.1158/1078-0432.CCR-1131-03", "14760096"]}, {"Citation": "Vabbilisetty P., Sun X.-L. Liposome surface functionalization based on different anchoring lipids via Staudinger ligation. Org. Biomol. Cem. 2014;12:1237\u20131244. doi: 10.1039/c3ob41721b.", "ArticleIdList": ["10.1039/c3ob41721b", "PMC3955738", "24413731"]}, {"Citation": "Nobs L., Buchegger F., Gurny R., All\u00e9mann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 2004;93:1980\u20131992. doi: 10.1002/jps.20098.", "ArticleIdList": ["10.1002/jps.20098", "15236448"]}, {"Citation": "Richter R.P., B\u00e9rat R., Brisson A.R. Formation of solid-supported lipid bilayers: an integrated view. Langmuir. 2006;22:3497\u20133505. doi: 10.1021/la052687c.", "ArticleIdList": ["10.1021/la052687c", "16584220"]}, {"Citation": "Troutier A.-L., Ladavi\u00e8re C. An overview of lipid membrane supported by colloidal particles. Adv. Colloid Interf. Sci. 2007;133:1\u201321. doi: 10.1016/j.cis.2007.02.003.", "ArticleIdList": ["10.1016/j.cis.2007.02.003", "17397791"]}, {"Citation": "Mornet S., Lambert O., Duguet E., Brisson A. The formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy. Nano Lett. 2005;5:281\u2013285. doi: 10.1021/nl048153y.", "ArticleIdList": ["10.1021/nl048153y", "15794611"]}, {"Citation": "Peetla C., Stine A., Labhasetwar V. Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol. Pharm. 2009;6:1264\u20131276. doi: 10.1021/mp9000662.", "ArticleIdList": ["10.1021/mp9000662", "PMC2757518", "19432455"]}, {"Citation": "Michot J.-M., Seral C., Van Bambeke F., Mingeot-Leclercq M.-P., Tulkens P.M. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob. Agents Chemother. 2005;49:2429\u20132437. doi: 10.1128/AAC.49.6.2429-2437.2005.", "ArticleIdList": ["10.1128/AAC.49.6.2429-2437.2005", "PMC1140503", "15917543"]}, {"Citation": "Bensikaddour H., Snoussi K., Lins L., Van Bambeke F., Tulkens P.M., Brasseur R., Goormaghtigh E., Mingeot-Leclercq M.-P. Interactions of ciprofloxacin with DPPC and DPPG: fluorescence anisotropy, ATR-FTIR and 31 P NMR spectroscopies and conformational analysis. Biochim. Biophys. Acta. 2008;1778:2535\u20132543. doi: 10.1016/j.bbamem.2008.08.015.", "ArticleIdList": ["10.1016/j.bbamem.2008.08.015", "18809375"]}, {"Citation": "Fa N., Lins L., Courtoy P.J., Dufr\u00eane Y., Van Der Smissen P., Brasseur R., Tyteca D., Mingeot-Leclercq M.-P. Decrease of elastic moduli of DOPC bilayers induced by a macrolide antibiotic, azithromycin. Biochim. Biophys. Acta. 2007;1768:1830\u20131838. doi: 10.1016/j.bbamem.2007.04.013.", "ArticleIdList": ["10.1016/j.bbamem.2007.04.013", "17537401"]}, {"Citation": "Klopman G., Zhu H. Recent methodologies for the estimation of n-octanol/water partition coefficients and their use in the prediction of membrane transport properties of drugs. Mini Rev. Med. Chem. 2005;5:127\u2013133. doi: 10.2174/1389557053402765.", "ArticleIdList": ["10.2174/1389557053402765", "15720283"]}, {"Citation": "Rodrigues C., Gameiro P., Reis S., Lima J., de Castro B. Derivative spectrophotometry as a tool for the determination of drug partition coefficients in water/dimyristoyl-L-\u03b1-phosphatidylglycerol (DMPG) liposomes. Biophys. Chem. 2001;94:97\u2013106. doi: 10.1016/S0301-4622(01)00227-7.", "ArticleIdList": ["10.1016/S0301-4622(01)00227-7", "11744194"]}, {"Citation": "Baciu M., Sebai S.C., Ces O., Mulet X., Clarke J.A., Shearman G.C., Law R.V., Templer R.H., Plisson C., Parker C.A. Degradative transport of cationic amphiphilic drugs across phospholipid bilayers. Philos. Trans. Roy. Soc. Lond. A. 2006;364:2597\u20132614. doi: 10.1098/rsta.2006.1842.", "ArticleIdList": ["10.1098/rsta.2006.1842", "16973478"]}, {"Citation": "Pavinatto F.J., Caseli L., Pavinatto A., dos Santos D.S., Nobre T.M., Zaniquelli M.E., Silva H.S., Miranda P.B., de Oliveira O.N. Probing chitosan and phospholipid interactions using Langmuir and Langmuir\u2212 Blodgett films as cell membrane models. Langmuir. 2007;23:7666\u20137671. doi: 10.1021/la700856a.", "ArticleIdList": ["10.1021/la700856a", "17539668"]}, {"Citation": "Yusupov M., Van der Paal J., Neyts E., Bogaerts A. Synergistic effect of electric field and lipid oxidation on the permeability of cell membranes. Biochim. Biophys. Acta. 2017;1861:839\u2013847. doi: 10.1016/j.bbagen.2017.01.030.", "ArticleIdList": ["10.1016/j.bbagen.2017.01.030", "28137619"]}, {"Citation": "Phillips M.A., Gran M.L., Peppas N.A. Targeted nanodelivery of drugs and diagnostics. Nano Today. 2010;5:143\u2013159. doi: 10.1016/j.nantod.2010.03.003.", "ArticleIdList": ["10.1016/j.nantod.2010.03.003", "PMC2882307", "20543895"]}, {"Citation": "Huynh R., Chaubet F., Jozefonvicz J. Anticoagulant properties of dextranmethylcarboxylate benzylamide sulfate (DMCBSu); a new generation of bioactive functionalized dextran. Carbohydr. Res. 2001;332:75\u201383. doi: 10.1016/S0008-6215(01)00066-0.", "ArticleIdList": ["10.1016/S0008-6215(01)00066-0", "11403090"]}, {"Citation": "Barrera C., Herrera A.P., Rinaldi C. Colloidal dispersions of monodisperse magnetite nanoparticles modified with poly (ethylene glycol) J. Colloid Interface Sci. 2009;329:107\u2013113. doi: 10.1016/j.jcis.2008.09.071.", "ArticleIdList": ["10.1016/j.jcis.2008.09.071", "18930466"]}, {"Citation": "Gopalakrishnan G., Danelon C., Izewska P., Prummer M., Bolinger P.Y., Geissb\u00fchler I., Demurtas D., Dubochet J., Vogel H. Multifunctional lipid/quantum dot hybrid nanocontainers for controlled targeting of live cells. Angew. Chem. 2006;45:5478\u20135483. doi: 10.1002/anie.200600545.", "ArticleIdList": ["10.1002/anie.200600545", "16847983"]}, {"Citation": "Matsuno R., Ishihara K. Integrated functional nanocolloids covered with artificial cell membranes for biomedical applications. Nano Today. 2011;6:61\u201374. doi: 10.1016/j.nantod.2010.12.009.", "ArticleIdList": ["10.1016/j.nantod.2010.12.009"]}, {"Citation": "Thanh N.T., Green L.A. Functionalisation of nanoparticles for biomedical applications. Nano Today. 2010;5:213\u2013230. doi: 10.1016/j.nantod.2010.05.003.", "ArticleIdList": ["10.1016/j.nantod.2010.05.003"]}, {"Citation": "Dubertret B., Skourides P., Norris D.J., Noireaux V., Brivanlou A.H., Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002;298:1759\u20131762. doi: 10.1126/science.1077194.", "ArticleIdList": ["10.1126/science.1077194", "12459582"]}, {"Citation": "Hyodo K., Yamamoto E., Suzuki T., Kikuchi H., Asano M., Ishihara H. Development of liposomal anticancer drugs. Biol. Pharm. Bull. 2013;36:703\u2013707. doi: 10.1248/bpb.b12-01106.", "ArticleIdList": ["10.1248/bpb.b12-01106", "23649329"]}, {"Citation": "Dhoot N.O., Wheatley M.A. Microencapsulated liposomes in controlled drug delivery: strategies to modulate drug release and eliminate the burst effect. J. Pharm. Sci. 2003;92:679\u2013689. doi: 10.1002/jps.19104.", "ArticleIdList": ["10.1002/jps.19104", "12587129"]}, {"Citation": "Kim S. DepoFoam-mediated drug delivery into cerebrospinal fluid. Methods Neurosci. 1994;21:118\u2013131."}, {"Citation": "Kim S., Turker M.S., Chi E.Y., Sela S., Martin G.M. Preparation of multivesicular liposomes. Biochim. Biophys. Acta. 1983;728:339\u2013348. doi: 10.1016/0005-2736(83)90504-7.", "ArticleIdList": ["10.1016/0005-2736(83)90504-7", "6824663"]}, {"Citation": "Liu L., Ye Q., Lu M., Chen S.-T., Tseng H.-W., Lo Y.-C., Ho C. A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid. Sci. Rep. 2017;7:16106. doi: 10.1038/s41598-017-16293-6.", "ArticleIdList": ["10.1038/s41598-017-16293-6", "PMC5701028", "29170482"]}, {"Citation": "Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002;3:415\u2013424. doi: 10.1016/S1470-2045(02)00788-X.", "ArticleIdList": ["10.1016/S1470-2045(02)00788-X", "12142171"]}, {"Citation": "Eloy J.O., de Souza M.C., Petrilli R., Barcellos J.P.A., Lee R.J., Marchetti J.M. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf. B. 2014;123:345\u2013363. doi: 10.1016/j.colsurfb.2014.09.029.", "ArticleIdList": ["10.1016/j.colsurfb.2014.09.029", "25280609"]}, {"Citation": "He W., Hu X., Jiang W., Liu R., Zhang D., Zhang J., Li Z., Luan Y. Rational Design of a New Self-Codelivery System from Redox-Sensitive Camptothecin\u2013Cytarabine Conjugate Assembly for Effectively Synergistic Anticancer Therapy. Adv. Healthc. Mater. 2017;6:1700829. doi: 10.1002/adhm.201700829.", "ArticleIdList": ["10.1002/adhm.201700829", "29076266"]}, {"Citation": "Chhikara B.S., Parang K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin. Drug Deliv. 2010;7:1399\u20131414. doi: 10.1517/17425247.2010.527330.", "ArticleIdList": ["10.1517/17425247.2010.527330", "20964588"]}, {"Citation": "Benesch M., Urban C. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin. Pharm. 2008;9:301\u2013309. doi: 10.1517/14656566.9.2.301.", "ArticleIdList": ["10.1517/14656566.9.2.301", "18201152"]}, {"Citation": "Phuphanich S., Maria B., Braeckman R., Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt\u00ae) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J. Neurooncol. 2007;81:201\u2013208. doi: 10.1007/s11060-006-9218-x.", "ArticleIdList": ["10.1007/s11060-006-9218-x", "16941075"]}, {"Citation": "Craig C. Current treatment approaches for neoplastic meningitis: Nursing management of patients receiving intrathecal DepoCyt. Oncol. Nurs. Forum. 2000;27:1225\u20131230.", "ArticleIdList": ["11013903"]}, {"Citation": "Goldberg M.S. Improving cancer immunotherapy through nanotechnology. Nat. Rev. Cancer. 2019;19:587\u2013602. doi: 10.1038/s41568-019-0186-9.", "ArticleIdList": ["10.1038/s41568-019-0186-9", "31492927"]}, {"Citation": "Cao W.M., Gao Y., Yang H.J., Xie S.N., Ding X.W., Pan Z.W., Ye W.W., Wang X.J. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer. BMC Cancer. 2016;16:64. doi: 10.1186/s12885-016-2107-6.", "ArticleIdList": ["10.1186/s12885-016-2107-6", "PMC4744435", "26852015"]}, {"Citation": "Wang J., Yin C., Tang G., Lin X., Wu Q. Glucose-functionalized multidrug-conjugating nanoparticles based on amphiphilic terpolymer with enhanced anti-tumorous cell cytotoxicity. Int. J. Pharm. 2013;441:291\u2013298. doi: 10.1016/j.ijpharm.2012.11.030.", "ArticleIdList": ["10.1016/j.ijpharm.2012.11.030", "23194888"]}, {"Citation": "Sharma P., Dube B., Sawant K. Synthesis of cytarabine lipid drug conjugate for treatment of meningeal leukemia: Development, characterization and in vitro cell line studies. J. Biomed. Nanotechnol. 2012;8:928\u2013937. doi: 10.1166/jbn.2012.1464.", "ArticleIdList": ["10.1166/jbn.2012.1464", "23030001"]}, {"Citation": "Pentak D., Maciazek-Jurczyk M., Zawada Z.H. The role of nanoparticles in the albumin-cytarabine and albumin-methotrexate interactions. Mater. Sci. Eng. C Mater. Biol. Appl. 2017;73:388\u2013397. doi: 10.1016/j.msec.2016.12.055.", "ArticleIdList": ["10.1016/j.msec.2016.12.055", "28183623"]}, {"Citation": "Yin C., Li X., Wu Q., Wang J.L., Lin X.F. Multidrug nanoparticles based on novel random copolymer containing cytarabine and fluorodeoxyuridine. J. Colloid Interface Sci. 2010;349:153\u2013158. doi: 10.1016/j.jcis.2010.05.028.", "ArticleIdList": ["10.1016/j.jcis.2010.05.028", "20621810"]}, {"Citation": "Khan H., Shukla R.N., Bajpai A.K. Genipin-modified gelatin nanocarriers as swelling controlled drug delivery system for in vitro release of cytarabine. Mater. Sci. Eng. C Mater. Biol. Appl. 2016;61:457\u2013465. doi: 10.1016/j.msec.2015.12.085.", "ArticleIdList": ["10.1016/j.msec.2015.12.085", "26838872"]}, {"Citation": "Yadav K.S., Sawant K.K. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS PharmSciTech. 2010;11:1456\u20131465. doi: 10.1208/s12249-010-9519-4.", "ArticleIdList": ["10.1208/s12249-010-9519-4", "PMC2974135", "20842542"]}, {"Citation": "Yadav K.S., Jacob S., Sachdeva G., Chuttani K., Mishra A.K., Sawant K.K. Long circulating PEGylated PLGA nanoparticles of cytarabine for targeting leukemia. J. Microencapsul. 2011;28:729\u2013742. doi: 10.3109/02652048.2011.615949.", "ArticleIdList": ["10.3109/02652048.2011.615949", "21970655"]}, {"Citation": "Pawar H.R., Bhosale S.S., Derle N.D. Use of liposomes in cancer therapy: A review. Int. J. Pharm. Sci. Res. 2012;3:3585."}, {"Citation": "Kang L., Gao Z., Huang W., Jin M., Wang Q. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm. Sin. B. 2015;5:169\u2013175. doi: 10.1016/j.apsb.2015.03.001.", "ArticleIdList": ["10.1016/j.apsb.2015.03.001", "PMC4629232", "26579443"]}, {"Citation": "Aghebati-maleki L., Salehi B., Behfar R., Saeidmanesh H., Ahmadian F., Sarebanhassanabadi M., Negahdary M. Designing a hydrogen peroxide biosensor using catalase and modified electrode with magnesium oxide nanoparticles. Int. J. Electrochem. Sci. 2014;9:257\u2013271."}, {"Citation": "Sistani P., Sofimaryo L., Masoudi Z.R., Sayad A., Rahimzadeh R., Salehi B. A penicillin biosensor by using silver nanoparticles. Int. J. Electrochem. Sci. 2014;9:6201\u20136212."}, {"Citation": "Salehi B., Mehrabian S., Ahmadi M. Investigation of antibacterial effect of Cadmium Oxide nanoparticles on Staphylococcus Aureus bacteria. J. nanobiotechnol. 2014;12:26. doi: 10.1186/s12951-014-0026-8.", "ArticleIdList": ["10.1186/s12951-014-0026-8", "PMC4227281", "25056250"]}, {"Citation": "Noble G.T., Stefanick J.F., Ashley J.D., Kiziltepe T., Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32:32\u201345. doi: 10.1016/j.tibtech.2013.09.007.", "ArticleIdList": ["10.1016/j.tibtech.2013.09.007", "24210498"]}, {"Citation": "Slingerland M., Guchelaar H.-J., Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov. Today. 2012;17:160\u2013166. doi: 10.1016/j.drudis.2011.09.015.", "ArticleIdList": ["10.1016/j.drudis.2011.09.015", "21983329"]}, {"Citation": "Allen T.M., Cullis P.R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 2013;65:36\u201348. doi: 10.1016/j.addr.2012.09.037.", "ArticleIdList": ["10.1016/j.addr.2012.09.037", "23036225"]}, {"Citation": "Olusanya T.O.B., Haj Ahmad R.R., Ibegbu D.M., Smith J.R., Elkordy A.A. Liposomal Drug Delivery Systems and Anticancer Drugs. Molecules. 2018;23:907. doi: 10.3390/molecules23040907.", "ArticleIdList": ["10.3390/molecules23040907", "PMC6017847", "29662019"]}, {"Citation": "Jha S., Sharma P.K., Malviya R. Liposomal Drug Delivery System for Cancer Therapy: Advancement and Patents. Recent Patents Drug Deliv. Formul. 2016;10:177\u2013183.", "ArticleIdList": ["27712569"]}, {"Citation": "Petre C.E., Dittmer D.P. Liposomal daunorubicin as treatment for Kaposi\u2019s sarcoma. Int. J. Nanomed. 2007;2:277\u2013288.", "ArticleIdList": ["PMC2676651", "18019828"]}, {"Citation": "Hardiansyah A., Huang L.Y., Yang M.C., Liu T.Y., Tsai S.C., Yang C.Y., Kuo C.Y., Chan T.Y., Zou H.M., Lian W.N., et al. Magnetic liposomes for colorectal cancer cells therapy by high-frequency magnetic field treatment. Nanoscale Res. Lett. 2014;9:497. doi: 10.1186/1556-276X-9-497.", "ArticleIdList": ["10.1186/1556-276X-9-497", "PMC4169134", "25246875"]}, {"Citation": "Mock J.N., Costyn L.J., Wilding S.L., Arnold R.D., Cummings B.S. Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer. Integr. Biol. 2013;5:172\u2013182. doi: 10.1039/c2ib20108a.", "ArticleIdList": ["10.1039/c2ib20108a", "PMC4164335", "22890797"]}, {"Citation": "Berlin Grace V.M., Viswanathan S. Pharmacokinetics and therapeutic efficiency of a novel cationic liposome nano-formulated all trans retinoic acid in lung cancer mice model. J. Drug Deliv. Sci. Technol. 2017;39:223\u2013236. doi: 10.1016/j.jddst.2017.04.005.", "ArticleIdList": ["10.1016/j.jddst.2017.04.005"]}, {"Citation": "Legut M., Lipka D., Filipczak N., Piwoni A., Kozubek A., Gubernator J. Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines\u2014in vitro studies. Int. J. Nanomed. 2014;9:653\u2013668.", "ArticleIdList": ["PMC3904835", "24489469"]}, {"Citation": "Wang-Gillam A., Li C.P., Bodoky G., Dean A., Shan Y.S., Jameson G., Macarulla T., Lee K.H., Cunningham D., Blanc J.F., et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545\u2013557. doi: 10.1016/S0140-6736(15)00986-1.", "ArticleIdList": ["10.1016/S0140-6736(15)00986-1", "26615328"]}, {"Citation": "Zhou J., Zhao W.Y., Ma X., Ju R.J., Li X.Y., Li N., Sun M.G., Shi J.F., Zhang C.X., Lu W.L. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials. 2013;34:3626\u20133638. doi: 10.1016/j.biomaterials.2013.01.078.", "ArticleIdList": ["10.1016/j.biomaterials.2013.01.078", "23422592"]}, {"Citation": "Gabizon A.A., Shmeeda H., Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 2006;16:175\u2013183. doi: 10.1080/08982100600848769.", "ArticleIdList": ["10.1080/08982100600848769", "16952872"]}, {"Citation": "Gratton S.E. Ph.D. Thesis. The University of North Carolina; Chapel Hill, NC, USA: 2008. In Vitro and In Vivo Studies of Nanomolded PRINT Particles of Precisely Controlled Size, Shape, and Surface Chemistry."}, {"Citation": "Hamada A., Kawaguchi T., Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin. Pharm. 2002;41:705\u2013718. doi: 10.2165/00003088-200241100-00002.", "ArticleIdList": ["10.2165/00003088-200241100-00002", "12162758"]}, {"Citation": "Evans J.S., Musser E.A., Mengel G.D., Forsblad K.R., Hunter J.H. Antitumor activity of 1-beta-D-arainofuranosylcytosine hydrochloride. Proc. Soc. Exp. Biol. Med. 1961;106:350\u2013353. doi: 10.3181/00379727-106-26335.", "ArticleIdList": ["10.3181/00379727-106-26335", "13697589"]}, {"Citation": "Talley R.W., Vaitkevicius V.K. Megaloblastosis produced by a cytosine antagonist, 1-beta-D-arabinofuranosylcytosine. Blood. 1963;21:352\u2013362. doi: 10.1182/blood.V21.3.352.352.", "ArticleIdList": ["10.1182/blood.V21.3.352.352", "13984786"]}, {"Citation": "Newman D.J., Cragg G.M., Battershill C.N. Therapeutic Agents from the Sea: Biodiversity, Chemo-Evolutionary Insight and Advances To the End of Darwin\u2019s 200th Year. National Library of Medicine; Bethesda, MD, USA: 2009.", "ArticleIdList": ["22752743"]}, {"Citation": "Tyner J.W., Tardi P., Mayer L., Fletcher L.B., Spurgeon S., Kovacsovics T., Loriaux M.M. Evaluation of CPX-351 (cytarabine: Daunorubicin) liposome injection anti-Leukemic activity against primary patient leukemia cells. Am. Soc. Hematol. 2010"}, {"Citation": "Hare J.I., Lammers T., Ashford M.B., Puri S., Storm G., Barry S.T. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 2017;108:25\u201338. doi: 10.1016/j.addr.2016.04.025.", "ArticleIdList": ["10.1016/j.addr.2016.04.025", "27137110"]}, {"Citation": "Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J. Control. Rel. 2012;161:175\u2013187. doi: 10.1016/j.jconrel.2011.09.063.", "ArticleIdList": ["10.1016/j.jconrel.2011.09.063", "21945285"]}, {"Citation": "Juzenas P., Chen W., Sun Y.-P., Coelho M.A.N., Generalov R., Generalova N., Christensen I.L. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv. Drug Deliv. Rev. 2008;60:1600\u20131614. doi: 10.1016/j.addr.2008.08.004.", "ArticleIdList": ["10.1016/j.addr.2008.08.004", "PMC2695009", "18840487"]}, {"Citation": "Bhojwani D., Pui C.-h. Intrathecal liposomal cytarabine: More friend than foe? Leuk. Lymphoma. 2008;49:1427\u20131430. doi: 10.1080/10428190802220527.", "ArticleIdList": ["10.1080/10428190802220527", "PMC2803076", "18766957"]}, {"Citation": "Kratz F., Senter P., Steinhagen H. Drug Delivery in Oncology: From Basic Research to Cancer Therapy. Volume 3 John Wiley & Sons; Hoboken, NJ, USA: 2013."}, {"Citation": "Bassan R., Masciulli A., Intermesoli T., Audisio E., Rossi G., Pogliani E.M., Cassibba V., Mattei D., Romani C., Cortelezzi A., et al. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. Haematologica. 2015;100:786\u2013793. doi: 10.3324/haematol.2014.123273.", "ArticleIdList": ["10.3324/haematol.2014.123273", "PMC4450624", "25749825"]}, {"Citation": "Egusquiaguirre S.P., Igartua M., Hern\u00e1ndez R.M., Pedraz J.L. Nanoparticle delivery systems for cancer therapy: Advances in clinical and preclinical research. Clin. Transl. Oncol. 2012;14:83\u201393. doi: 10.1007/s12094-012-0766-6.", "ArticleIdList": ["10.1007/s12094-012-0766-6", "22301396"]}, {"Citation": "Chamberlain M.C. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: A retrospective case series. J. Neurooncol. 2012;109:143\u2013148. doi: 10.1007/s11060-012-0880-x.", "ArticleIdList": ["10.1007/s11060-012-0880-x", "22539243"]}, {"Citation": "Kim S., Chatelut E., Kim J.C., Howell S.B., Cates C., Kormanik P.A., Chamberlain M.C. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J. Clin. Oncol. 1993;11:2186\u20132193. doi: 10.1200/JCO.1993.11.11.2186.", "ArticleIdList": ["10.1200/JCO.1993.11.11.2186", "8229133"]}, {"Citation": "Kohn F.R., Malkmus S.A., Brownson E.A., Rossi S.S., Yaksh T.L. Fate of the predominant phospholipid component of DepoFoamTM drug delivery matrix after intrathecal administration of sustained-release encapsulated cytarabine in rats. Drug Deliv. 1998;5:143\u2013151. doi: 10.3109/10717549809031390.", "ArticleIdList": ["10.3109/10717549809031390", "19570006"]}, {"Citation": "Wan S.H., Huffman D.H., Azarnoff D.L., Hoogstraten B., Larsen W.E. Pharmacokinetics of 1-\u03b2-D-arabinofuranosylcytosine in humans. Cancer Res. 1974;34:392\u2013397.", "ArticleIdList": ["4521089"]}, {"Citation": "Groothuis D.R., Benalcazar H., Allen C.V., Wise R.M., Dills C., Dobrescu C., Rothholtz V., Levy R.M. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res. 2000;856:281\u2013290. doi: 10.1016/S0006-8993(99)02089-2.", "ArticleIdList": ["10.1016/S0006-8993(99)02089-2", "10677637"]}, {"Citation": "Scott-Moncrieff J.C.R., Chan T.C., Samuels M.L., Cook J.R., Coppoc G.L., DeNicola D.B., Richardson R.C. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. Cancer Chemother. Pharmacol. 1991;29:13\u201318. doi: 10.1007/BF00686329.", "ArticleIdList": ["10.1007/BF00686329", "1742843"]}, {"Citation": "Tardi P., Johnstone S., Harasym N., Xie S., Harasym T., Zisman N., Harvie P., Bermudes D., Mayer L. In vivo maintenance of synergistic cytarabine: Daunorubicin ratios greatly enhances therapeutic efficacy. Leuk. Res. 2009;33:129\u2013139. doi: 10.1016/j.leukres.2008.06.028.", "ArticleIdList": ["10.1016/j.leukres.2008.06.028", "18676016"]}, {"Citation": "Bayne W.F., Mayer L.D., Swenson C.E. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J. Pharma. Sci. 2009;98:2540\u20132548. doi: 10.1002/jps.21620.", "ArticleIdList": ["10.1002/jps.21620", "19009594"]}, {"Citation": "Carol H., Fan M.M., Harasym T.O., Boehm I., Mayer L.D., Houghton P., Smith M.A., Lock R.B. Efficacy of CPX-351,(cytarabine: Daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. Pediatric Blood Cancer. 2015;62:65\u201371. doi: 10.1002/pbc.25133.", "ArticleIdList": ["10.1002/pbc.25133", "PMC4237711", "25203866"]}, {"Citation": "Dicko A., Kwak S., Frazier A.A., Mayer L.D., Liboiron B.D. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int. J. Pharma. 2010;391:248\u2013259. doi: 10.1016/j.ijpharm.2010.02.014.", "ArticleIdList": ["10.1016/j.ijpharm.2010.02.014", "20156541"]}, {"Citation": "Jabbour E., Cortes J.E., Giles F.J., O\u2019Brien S., Kantarjian H.M. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007;109:2171\u20132181. doi: 10.1002/cncr.22661.", "ArticleIdList": ["10.1002/cncr.22661", "17431887"]}, {"Citation": "Shah M., Agarwal B. Recent advances in management of acute myeloid leukemia (AML) Ind. J. Pediatrics. 2008;75:831\u2013837. doi: 10.1007/s12098-008-0155-x.", "ArticleIdList": ["10.1007/s12098-008-0155-x", "18769895"]}, {"Citation": "Drugs.com. Depocyt.  [(accessed on 1 June 2018)]; Available online:  https://www.drugs.com/pro/depocyt.html."}, {"Citation": "Chamberlain M.C., Khatibi S., Kim J.C., Howell S.B., Chatelut E., Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch. Neurol. 1993;50:261\u2013264. doi: 10.1001/archneur.1993.00540030027009.", "ArticleIdList": ["10.1001/archneur.1993.00540030027009", "8442704"]}, {"Citation": "Chamberlain M.C., Kormanik P., Howell S.B., Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch. Neurol. 1995;52:912\u2013917. doi: 10.1001/archneur.1995.00540330094020.", "ArticleIdList": ["10.1001/archneur.1995.00540330094020", "7661730"]}, {"Citation": "Mrugala M.M., Kim B., Sharma A., Johnson N., Graham C., Kurland B.F., Gralow J. Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer. Clin. Breast Cancer. 2019 doi: 10.1016/j.clbc.2019.04.004.", "ArticleIdList": ["10.1016/j.clbc.2019.04.004", "31175053"]}, {"Citation": "Glantz M.J., Jaeckle K.A., Chamberlain M.C., Phuphanich S., Recht L., Swinnen L.J., Maria B., LaFollette S., Schumann G.B., Cole B.F., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999;5:3394\u20133402.", "ArticleIdList": ["10589750"]}, {"Citation": "Beauchesne P., Blonski M., Brissart H. Response to intrathecal infusions of Depocyt(R) in secondary diffuse leptomeningeal gliomatosis. A case report. In vivo. 2011;25:991\u2013993.", "ArticleIdList": ["22021694"]}, {"Citation": "Zimm S., Collins J.M., Miser J., Chatterji D., Poplack D.G. Cytosine arabinoside cerebrospinal fluid kinetics. Clin. Pharmacol. Ther. 1984;35:826\u2013830. doi: 10.1038/clpt.1984.120.", "ArticleIdList": ["10.1038/clpt.1984.120", "6587957"]}, {"Citation": "Glantz M.J., LaFollette S., Jaeckle K.A., Shapiro W., Swinnen L., Rozental J.R., Phuphanich S., Rogers L.R., Gutheil J.C., Batchelor T., et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 1999;17:3110\u20133116. doi: 10.1200/JCO.1999.17.10.3110.", "ArticleIdList": ["10.1200/JCO.1999.17.10.3110", "10506606"]}, {"Citation": "Lassaletta A., Lopez-Ibor B., Mateos E., Gonzalez-Vicent M., Perez-Martinez A., Sevilla J., Diaz M.A., Madero L. Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors. J. Neurooncol. 2009;95:65\u201369. doi: 10.1007/s11060-009-9892-6.", "ArticleIdList": ["10.1007/s11060-009-9892-6", "19381444"]}, {"Citation": "Persons S. The decline of homeopathy\u2014the University of Iowa, 1876\u20131919. Bull. Hist. Med. 1991;65:74\u201387.", "ArticleIdList": ["2021694"]}, {"Citation": "Fleischhack G., Jaehde U., Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin. Pharm. 2005;44:1\u201331. doi: 10.2165/00003088-200544010-00001.", "ArticleIdList": ["10.2165/00003088-200544010-00001", "15634030"]}, {"Citation": "Angst M.S., Drover D.R. Pharmacology of drugs formulated with DepoFoam: A sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin. Pharm. 2006;45:1153\u20131176. doi: 10.2165/00003088-200645120-00002.", "ArticleIdList": ["10.2165/00003088-200645120-00002", "17112293"]}, {"Citation": "Bohn J.P., Reinstadler V., Pall G., Stockhammer G., Steurer M., Oberacher H., Wolf D. Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine. Eur. J. Drug. Metab. Pharm. 2019 doi: 10.1007/s13318-019-00572-w.", "ArticleIdList": ["10.1007/s13318-019-00572-w", "PMC6828631", "31435852"]}, {"Citation": "Chen K.T.J., Gilabert-Oriol R., Bally M.B., Leung A.W.Y. Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. Pharm. Res. 2019;36:125. doi: 10.1007/s11095-019-2654-z.", "ArticleIdList": ["10.1007/s11095-019-2654-z", "PMC6591181", "31236772"]}, {"Citation": "Mayer L.D., Tardi P., Louie A.C. CPX-351: A nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int. J. Nanomed. 2019;14:3819\u20133830. doi: 10.2147/IJN.S139450.", "ArticleIdList": ["10.2147/IJN.S139450", "PMC6537039", "31213803"]}, {"Citation": "Tolcher A.W., Mayer L.D. Improving combination cancer therapy: The CombiPlex((R)) development platform. Future Oncol. 2018;14:1317\u20131332. doi: 10.2217/fon-2017-0607.", "ArticleIdList": ["10.2217/fon-2017-0607", "29363994"]}]}], "History": [{"Year": "2019", "Month": "9", "Day": "17"}, {"Year": "2019", "Month": "11", "Day": "8"}, {"Year": "2019", "Month": "11", "Day": "14"}, {"Year": "2019", "Month": "11", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "11", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "8", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "12", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["31771220", "PMC6995526", "10.3390/biom9120773", "biom9120773"]}}]}